Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy...

Full description

Bibliographic Details
Main Authors: Praveen K. Bommareddy, Samuel D. Rabkin, Howard L. Kaufman
Format: Article
Language:English
Published: Taylor & Francis Group 2019-04-01
Series:OncoImmunology
Subjects:
immunotherapy
mek inhibition
melanoma
oncolytic virus
programmed cell death 1 (pd-1)
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1571390

Internet

http://dx.doi.org/10.1080/2162402X.2019.1571390

Similar Items